文献速递生殖医学

在体外受精/卵胞浆内单精子注射治疗的取卵过程中,虚拟现实并未减轻焦虑或疼痛:一项随机对照试验的结果

No anxiety or pain reduction by Virtual Reality during oocyte retrieval in IVF/ICSI treatment: results of a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2026-01-01

这项单中心、开放标签的随机对照试验于2023年2月至2024年8月开展,纳入113例接受体外受精/卵胞浆内单精子注射取卵的患者,比较在清醒镇静基础上加用虚拟现实与仅用清醒镇静的效果。结果显示两组在术前焦虑、术后焦虑、总体疼痛和峰值疼痛上均无显著差异。作者因此不建议将虚拟现实纳入常规焦虑和疼痛管理。

要点

  • 在清醒镇静基础上加用虚拟现实,未显著改善取卵患者的术前和术后焦虑。
  • 虚拟现实组与对照组的总体疼痛和峰值疼痛评分均无显著差异。
  • 作者不建议将虚拟现实纳入体外受精/卵胞浆内单精子注射的常规焦虑和疼痛管理。

核心结论

  • 虚拟现实对取卵患者的焦虑和疼痛无显著影响,作者不建议将其纳入常规焦虑和疼痛管理。

研究设计与样本

  • 单中心、开放标签、随机对照试验,于2023年2月至2024年8月开展,因干预性质未设盲。
  • 共纳入113例接受体外受精/卵胞浆内单精子注射取卵的患者,虚拟现实组57例,对照组56例。

主要发现

  • 术前焦虑:虚拟现实组与对照组均值差(MD)0.14(95%CI -1.78, 2.05),P=0.885。
  • 术后焦虑:MD 0.45(95%CI -1.21, 2.11),P=0.589。
  • 总体疼痛:MD -0.12(95%CI -0.97, 0.73),P=0.779。
  • 峰值疼痛:MD 0.59(95%CI -0.51, 1.68),P=0.287。

临床怎么用

  • 作者认为,由于虚拟现实对取卵患者的焦虑和疼痛无影响,不建议将其纳入体外受精/卵胞浆内单精子注射的常规焦虑和疼痛管理。
  • 作者建议未来研究应探索哪些亚组患者可能从虚拟现实中获益,以及如何以非药物方式实施干预研究。
  • 作者提出应考虑患者对体外受精/卵胞浆内单精子注射治疗期间焦虑和疼痛管理的偏好。

局限性

  • 虚拟现实可能仅对接受取卵的特定患者群体有效,或可能在减少术前焦虑方面更有效,进而可能减少操作相关疼痛。
  • 虚拟现实可能在达到某一阈值前可减轻疼痛,或在操作时间较短时有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the effect of Virtual Reality (VR) on anxiety and pain during oocyte retrieval in IVF/ICSI treatment? SUMMARY ANSWER: There is no significant effect of VR on anxiety and pain during oocyte retrieval in IVF/ICSI treatment. WHAT IS KNOWN ALREADY: Patients undergoing oocyte retrieval in IVF/ICSI treatment often experience anxiety and pain, despite conscious sedation. VR might offer a solution since it has been successful in reducing procedural anxiety and pain during medical procedures, with the potential to replace standard analgesic care. STUDY DESIGN, SIZE, DURATION: A single-centre, open-label, randomized controlled trial was conducted between February 2023 and August 2024. Due to the nature of the intervention, the study was not blinded. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients undergoing oocyte retrieval as part of IVF/ICSI treatment were screened. After providing informed consent, participants were randomized between oocyte retrieval with VR added to conscious sedation and oocyte retrieval with conscious sedation only. When assigned to the intervention group, patients received the VR intervention through a head-mounted device, showing nature films and relaxation exercises. This was added to standard care which includes analgesia and sedatives. Sounds were delivered through the head-mounted device or headphones. The primary outcome was pre- and post-procedural anxiety, measured using the STAI questionnaire. Secondary outcomes included procedural pain (NRS, scale 0-10), satisfaction scores (NRS, scale 0-10), VR preferences, and side effects. MAIN RESULTS AND THE ROLE OF CHANCE: There were 113 participants included: 57 in the intervention group receiving VR and 56 in the control group not receiving VR. We observed no differences between the intervention and control groups in pre-procedural anxiety (mean difference (MD) 0.14 (95% CI -1.78, 2.05), P = 0.885), post-procedural anxiety (MD 0.45 (95% CI -1.21, 2.11), P = 0.589), overall pain (MD -0.12 (95% CI -0.97, 0.73), P = 0.779), and peak pain (MD 0.59 (-0.51, 1.68), P = 0.287). LIMITATIONS, REASONS FOR CAUTION: VR might only be effective for a certain group of patients undergoing retrieval, or might be more effective in reducing pre-procedural anxiety, which in turn might lead to a reduction in procedural pain. Furthermore, it might reduce pain up to a certain threshold, or be effective when the duration of the procedure is short. WIDER IMPLICATIONS OF THE FINDINGS: Since VR does not affect anxiety and pain for the general patient population undergoing oocyte retrieval, we do not advise incorporating VR to standard IVF/ICSI anxiety and pain management. For future studies, it is important to investigate which subgroup could benefit from VR and how it could be implemented to study interventions from a non-pharmacological approach. Patient preferences regarding anxiety and pain management during IVF/ICSI treatment should be considered. STUDY FUNDING/COMPETING INTEREST(S): External funding from ZonMw (Grant number 838002978), the Implementation and Scale-up Coaching, and the Eggcelent Change grant from Theramex have been received for this study to cover the costs of the VR devices. A.P.v.H. and K.R. report to have received a travel grant from Merck to visit ESHRE 2022. A.M.F.S. reports to have been an invited speaker at ESHRE where travel and hotel costs are covered. V.M. reports to have received institutional research grants from Guerbet, Merck, and Ferring. He has received travel and speaker's fees from Guerbet. J.W.K. reports to be on the Advisory board of Boston Scientific, Saluda, Nevro, Abbott, and Medtronic, and received consulting fees from these organizations. He is a board member of the BNS. KD reports to have received an institutional research grant from Guerbet, a speaker's fee from Guerbet, and financial support to attend meetings by Merck and Guerbet. TRIAL REGISTRATION NUMBER: NCT05555498. TRIAL REGISTRATION DATE: 26 September 2022. DATE OF FIRST PATIENT’S ENROLMENT: 7 February 2023.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. van Haaps AP, Schreurs AMF, Rosielle K, et al. No anxiety or pain reduction by Virtual Reality during oocyte retrieval in IVF/ICSI treatment: results of a randomized controlled trial. Hum Reprod. 2026. PMID: 41057042. doi:10.1093/humrep/deaf193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。